Tyrus603
10時間前
Good to be back and fully invested in the same stock as you again, my friend!
Another scouring of the penny market led me here, and to discover-- voila! -- that my favorite Multi Bag maestro is already here.
I'm all for another instance of deja vu-room vroom! too. As, when we joined in on that previous stock together.(which DID in fact run up 10 bags between June 2021 and summer of 2022, before its crash) that happened to be the year immediately following a contentious election, exactly four years ago, after which we all, finally, put the political strife of a presidential election year and inauguration behind us, and turned our attention back fully to the multiple penny stocks making epic runups in 2021.
May 2025 bring us similar luck!
And why not?
Aren't the ups and downs of the market supposed to be cyclical? I say yes, let's go!
timberwolf7
2週前
I agree. Less than 30 days now to the fdas decision on
the NDA submission.
No secret there are 'some' that trade biotech company
'events'.
Been telling the few that I chat with, IF the NDA is accepted
for review, expect a little bounce in the share price on the news.
Again, I have never invested in a company making a 'pain reliever' before.
So a little wary with regard to the robustness of the clinical trials they ran in
terms of will they be 'good enough'. And most of my biotech investments
tho, have centered on finding a development that fits a serious NEED vs
is just a bit better than whats already out there (that in this case, doesn't seem
to 'work' for people)
disclaimer: own shares, and might be time to make that one last add
Invest-in-America
2週前
TNXP: Soaring in the Post-Market, right now. (See below what COPILOT as to say about it.)
"Why is TNXP stock soaring by 68% in the Post-M right now, 11-19-24? Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) stock is soaring today due to positive investor sentiment ahead of their Chief Operating Officer, Jessica Morris, presenting at the Winter 2024 Investor Summit. This event is generating excitement and optimism among investors about the company's future prospects1. Additionally, Tonix Pharmaceuticals has been making significant strides in its product pipeline, including the development of TNX-102 SL for fibromyalgia and TNX-4200 for antiviral treatments. These advancements are likely contributing to the stock's surge. Are you considering investing in TNXP, or are you just curious about the recent developments?"
https://www.tonixpharma.com/jessica-edgar-morris/
/////////////////////////////////////////////////////////////////////////////////////////
Frankestin
3週前
https://www.sec.gov/ix?doc=/Archives/edgar/data/1430306/000183988224038453/tnxp-8k_110824.htm
TNX-1700 (hTFF2-HSA) appears to be a very promising candidate for the treatment of gastric and colorectal cancer, with an innovative mechanism of action that addresses immune inhibition in the tumor microenvironment. The synergy with immune checkpoint inhibitors, favorable preclinical results and the blood-life prolongation approach through fusion with albumin suggest that this drug could represent an effective new therapeutic option, particularly for patients who do not respond to conventional treatments.
Dr. Timothy Wang leading the research, increasing credibility and the possibility of long-term success.
Innovative mechanism of action:
Reduce immune inhibition in the tumor microenvironment (TME), in particular by reducing MDSCs (myeloid-derived suppressor cells) that prevent the effectiveness of immune responses against the tumor.
Synergy with immune checkpoint inhibitors (anti-PD-1):
Greater combined efficacy: TNX-1700 enhances the immune response when combined with anti-PD-1 drugs, as shown in preclinical models of colorectal and gastric cancers.
Promising preclinical evidence:
Robust data in animal models of orthotopic and metastatic tumors showing significant reduction in tumor growth, metastasis and improved survival.
Increased tumor-infiltrating CD8+ T cells, suggesting an improved immune response.
Albumin technology for blood life extension:
Fusion with albumin increases the pharmacokinetics of the drug, reducing the frequency of administration and improving the duration of the therapeutic effect.
it's all nice… very large market! but it takes a lot of money to approve it! maybe in another 7 R/S
timberwolf7
1月前
Looking at the 3 Clinical Trials to see what 'happened'..
The one that ended in 2020 passed based on the end points.
The 2nd trial, RALLY, that followed did NOT meet the end points and I wanted to know
WHY it didn't, WHY it failed. At this link is an explanation for why it didn't pass. And tho
it didn't 'pass' cause of 'adverse' effects (see the write up for their explanation), they did state
that the results were otherwise 'consistent' with the first trial results.
https://ir.tonixpharma.com/news-events/press-releases/detail/1304/tonix-pharmaceuticals-announces-phase-3-rally-study-results
So they then started the RESILIENT trial that then passed.
So to sum it up, they ran 3 trials that based on their analysis met the trial endpoints with enough
stat significance to pass, and warrant their NDA submission that just took place. So given this, it
would APPEAR that this should be enough for the fda to accept the submission for review. The only
question that remains at this point is, was the trial 'robust' enough for the fda to say, we agree with the data
that the development does achieve its goal, that it helps people.
TBD'd.. NOTE: this review of the trials, the outcome was my priority when I had a chance even tho
I had already bought shares based on what I initially read. After what just happened to another favorite
of mine (ATNM where the fda concured in trial passed, but they screwed the company over by saying, for
reasons, you now have to run another PH 3 despite the evidence that the development WORKS/HELPS people)
I no longer can trust the trial results even if they are really good, to be 'good' enough anymore..
disclaimer: own shares
timberwolf7
1月前
Financials, shares outstanding...Market cap..
OK, like a lot of baby bios with an idea they are trying to push
across the finish line, they are financially strapped for cash. So
even if the fda accepts their NDA, expecting them to do a few more
secondarys/ATMs to raise cash (ie, dilution). But it is an evil
necessity and long term its impact will be on the target price it might
eventually get.
Shares outstanding: see on Yahoo its 22 Mil in the FLOAT, but 140 Mil
'authorized' (available for use in an ATM??)
Market Cap: at least its 'reasonable' vs way overvalued.